POSB35 Systematic Literature Review of the Epidemiology, Patient Characteristics, Treatments, Clinical, and Economic Outcomes Associated with Psoriasis in China and Taiwan

To systematically review and summarize the real-world evidence for epidemiology, patient characteristics, treatments, clinical and economic outcomes of psoriasis in Mainland China and Taiwan. English (MEDLINE, EMBASE, Web of Sciences, and The Cochrane Library) and Chinese databases (WANFANG, CNKI, and VIP) were searched for relevant real-world evidence published from 2005 to 2020. Single-arm meta-analysis and weighted average methods were used for evidence synthesis. Costs were adjusted to local currency in 2020. Four hundred forty-two observational studies from China and 117 from Taiwan were included. China had more prevalent psoriasis than Taiwan (crude prevalence: 590/100,000 vs. 251/100,000). The pooled estimates in China and Taiwan, respectively, included: psoriasis onset age (33.4 years vs. 34.4 years), psoriasis vulgaris distribution (78.4% vs. 80.2%), Psoriasis Area and Severity Index (PASI: 16.1 vs. 16.2), and quality of life measured by time trade-off (0.649 vs. 0.744). In patients with moderate-to-severe psoriasis, 29.9% used biologics in China and 78.4% in Taiwan. The treatment discontinuation rate of systemic therapy (including oral, intravenous, and subcutaneous administration treatments) was 63.6% in China and 64.6% in Taiwan. Lacking treatment effect was the main reason to discontinue biologics (59.3% to 70.8%). Longer treatment with biologics, including infliximab (PASI-90: 31.0% at 13th month vs. 47.6% at 6th month) and ustekinumab (PASI-90: 30.3% at 7th month vs. 27.3% at 4th month), didn’t further improve treatment outcomes. Patients with moderate-to-severe psoriasis who used biologics had higher hospital costs per episode in China (¥16,372 vs. ¥7,461) and higher annual medical costs in Taiwan (NTD 595,166 vs. NTD 195,449) than those not using biologics. Suboptimal outcomes in patients with psoriasis and high medical costs in patients with moderate-to-severe psoriasis who used biologics were observed in China and Taiwan real-world settings. The disease burden and unmet needs for psoriasis in China and Taiwan remained high.